CART-ddBCMA
arcellx
['multiple myeloma', 'cart,(-cartitude)', 'arcellx']
today, arcellx announced continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 annual meeting. read the full press release: #arcellx
#asco22 
We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.